Literature DB >> 894916

Host responses to hepatitis B infection in patients in a chronic hemodialysis unit.

W T London, J S Drew, E D Lustbader, B G Werner, B S Blumberg.   

Abstract

Host responses to hepatitis B infection were studied in 222 patients in a chronic hemodialysis unit. From 1970 to 1976, patients were monitored monthly for development of hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), and serum transaminase (SGPT) elevations. Five categories of patients were identified as: 1) chronic carriers of HBsAg; 2) transiently HBsAg(+), who developed anti-HBs; 3) HBsAg(-) on admission, who developed anti-HBs without becoming HBsAg(+); 4) anti-HBs(+) on admission; 5) uninfected who remained HBsAg(-) and anti-HBs(-). For a patient who became HBsAg(+) in this clinic, the probability of becoming a chronic carrier was 62-8% and rose to 88.5% if he or she had been HBsAg(+) for five consecutive months. Males were more likely to become chronic carriers, and females were more likely to develop anti-HBs. Neither age, race, nor type of underlying kidney disease was associated with particular host responses to hepatitis B virus. No effect of hepatitis B infection on mortality was detected. Variation in host response to hepatitis B infection among renal dialysis patients may affect the usefulness of hepatitis B hyperimmune globulin and hepatitis B vaccine and be related to the outcome of kidney transplantation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 894916     DOI: 10.1038/ki.1977.78

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

Review 1.  The use of vaccines in renal failure.

Authors:  D W Johnson; S J Fleming
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Infections in hemodialysis: a concise review. Part II: blood transmitted viral infections.

Authors:  T Eleftheriadis; V Liakopoulos; K Leivaditis; G Antoniadi; I Stefanidis
Journal:  Hippokratia       Date:  2011-04       Impact factor: 0.471

Review 3.  Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

4.  A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.

Authors:  E Z Oddone; P A Cowper; J D Hamilton; J R Feussner
Journal:  Health Serv Res       Date:  1993-04       Impact factor: 3.402

5.  Changes in serum iron levels due to infection with hepatitis B virus.

Authors:  B S Blumberg; E D Lustbader; P L Whitford
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

6.  Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants.

Authors:  Mohammad Hossein Somi; Babak Hajipour
Journal:  ISRN Gastroenterol       Date:  2012-09-18

Review 7.  Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.

Authors:  Joan Kha-Tu Ho; Beena Jeevan-Raj; Hans-Jürgen Netter
Journal:  Viruses       Date:  2020-01-21       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.